Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      PSS D
      PSS M

      UK-BNO-250045. DOP: May 2025.

      Post-stroke spasticity (PSS) has a significant impact on daily life6,7

       

      PSS has a significant impact on a stroke survivor’s daily life, impeding basic tasks, such as eating and self-care6,8,9

      Intermittent or sustained involuntary activation of muscles6

      separator

      Psychological consequences such as poor self-esteem and self image8

      separator

      Interference with balance and movement, including decline in ability to walk6,9

      separator

      Potential inability to perform activities of daily living and limit ability to engage in activities outside the home9

      separator

      Increased rate of fractures as a consequence of increased risk of falls9

      separator

      PSS: post-stroke spasticity.

      IDENTIFY AND MANAGE YOUR PSS PATIENTS

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora SK, et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358–73
      3. Blumenfeld AM, et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Kheder A and Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol 2012;12(5):289–98
      7. Urban PP, et al. Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke 2010;41(9):2016–20
      8. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines 2018. Available at: https://www.rcp.ac.uk/improving-care/resources/spasticity-in-adults-management-using-botulinum-toxin/. Accessed June 2025
      9. Esquenazi A. The human and economic burden of post-stroke spasticity and muscle overactivity. JCOM 2011;18:607–14

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora SK, et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358–73
      3. Blumenfeld AM, et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Kheder A and Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol 2012;12(5):289–98
      7. Urban PP, et al. Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke 2010;41(9):2016–20
      8. Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines 2018. Available at: https://www.rcp.ac.uk/improving-care/resources/spasticity-in-adults-management-using-botulinum-toxin/. Accessed June 2025
      9. Esquenazi A. The human and economic burden of post-stroke spasticity and muscle overactivity. JCOM 2011;18:607–14

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BTX-250070.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.